Ipsen Innovation
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$13.6M
Doctors Paid
188
Transactions
6,490
2024 Total
$5.8M
Payment Breakdown by Category
Research$11.7M (86.2%)
Consulting$1.0M (7.5%)
Travel$411,897 (3.0%)
Food & Beverage$62,832 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.7M | 5,628 | 86.2% |
| Consulting Fee | $1.0M | 220 | 7.5% |
| Travel and Lodging | $411,897 | 287 | 3.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $248,844 | 42 | 1.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $89,719 | 26 | 0.7% |
| Food and Beverage | $62,832 | 282 | 0.5% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $44,522 | 5 | 0.3% |
Payments by Type
Research
$11.7M
5,628 transactions
General
$1.9M
862 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus | $2.3M | 3 | 308 |
| Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | $2.2M | 3 | 2,236 |
| A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | $1.9M | 2 | 1,931 |
| A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis | $1.7M | 0 | 516 |
| A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | $1.4M | 8 | 274 |
| A Phase III, Multicentre, Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety Of DYSPORT Used In The Treatment Of Upper Limb Spasticity In Children | $1.4M | 0 | 140 |
| A Phase II, Multicentre, Double-blind, Randomised, Placebo Controlled, Dose Escalation and Dose Finding Study to Evaluate the Efficacy and Safety of Dysport in Vulvodynia Patients | $464,881 | 1 | 139 |
| Dysport Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity NDO Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 CONTENT1 | $59,196 | 0 | 10 |
| A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults | $53,584 | 0 | 47 |
| ArmA | $44,669 | 0 | 3 |
| A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment | $22,670 | 1 | 8 |
| Validation of Patient Reported Outcome Measures for Use in Vulvodynia | $11,750 | 0 | 2 |
| A Phase III, Multicentre,Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety OfDYSPORTUsed In The Treatment Of Upper Limb Spasticity In Children | $11,222 | 0 | 4 |
| Validation of the modified Foot Function Index mFFI for Use in Hallux Valgus | $8,915 | 0 | 2 |
| Validation of the Modified Foot Function IndexmFFI for Use in Hallux Valgus | $4,995 | 0 | 4 |
| International Multicentre Validation Study ofSAGIT Instrument in Acromegaly | $1,256 | 1 | 1 |
| A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport For The Treatment Of UrinaryIncontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis | $225.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 4
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Mark Gormley, Md, MD | Physical Medicine & Rehabilitation | Saint Paul, MN | $5,690 | $0 |
| Joyce Oleszek, Md, MD | Pediatric Rehabilitation Medicine | Aurora, CO | $5,461 | $0 |
| Dr. Shlomo Melmed, M.d, M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $5,405 | $0 |
| Justin Kung | Diagnostic Radiology | Boston, MA | $5,400 | $0 |
| Dr. Edward Dabrowski, M.d, M.D | Physical Medicine & Rehabilitation | Roseville, MI | $5,311 | $0 |
| Dr. Wuwei Feng, Md Ms, MD MS | Neurology | Charleston, SC | $5,025 | $0 |
| Dr. John Bilezikian, M.d, M.D | Endocrinology, Diabetes & Metabolism | New York, NY | $4,965 | $0 |
| Dr. Lawrence Lavery, D.p.m, D.P.M | Podiatrist | San Antonio, TX | $4,843 | $0 |
| Mr. Babak Baravarian, Dpm, DPM | Podiatrist | Santa Monica, CA | $4,801 | $0 |
| Cindy Ivanhoe, Md, MD | Physical Medicine & Rehabilitation | Houston, TX | $4,546 | $0 |
| Glynis Ablon, M.d, M.D | Dermatology | Manhattan Beach, CA | $4,505 | $0 |
| Ketan Patel, Md, MD | Plastic Surgery | Tarzana, CA | $4,335 | $0 |
| Dr. Steven Ross, M.d, M.D | Orthopaedic Surgery | Orange, CA | $4,226 | $0 |
| Dr. Mitchell Shiffman, Md, MD | Gastroenterology | Newport News, VA | $4,150 | $0 |
| David Harrild, M.d, M.D | Pediatric Cardiology | Boston, MA | $4,000 | $0 |
| Stephanie Wu, Dpm, DPM | Foot Surgery | North Chicago, IL | $3,972 | $0 |
| Alrabi Tawil, M.d, M.D | Neuropathology | Rochester, NY | $3,780 | $0 |
| Marlyn Mayo, Md, MD | Hepatology | Dallas, TX | $3,735 | $0 |
| John Vierling, Md, MD | Internal Medicine | Houston, TX | $3,735 | $0 |
| Dr. Nadia Ovchinsky | Pediatric Gastroenterology | New York, NY | $3,735 | $0 |
| Dr. James Boyer, M.d, M.D | Gastroenterology | New Haven, CT | $3,735 | $0 |
| Mr. James Tabibian, M.d, M.D | Gastroenterology | Glendale, CA | $3,735 | $0 |
| Prof. Giuseppe Giaccone | Specialist | Bethesda, MD | $3,703 | $0 |
| Dr. Gary Brenner, Md Phd, MD PHD | Pain Medicine | Boston, MA | $3,660 | $0 |
| Dr. Zbigniew Lorenc, M.d., F.a.c.s, M.D., F.A.C.S | Plastic Surgery | New York, NY | $3,515 | $0 |
Ad
Top Products
- Dysport $6.4M
- DYSPORT $3.5M
Associated Products (4)
- Dysport $16.6M
- DYSPORT $8.5M
- Dysport 300 U-1 $2.8M
- Somatuline $12,137
Payment Categories
- Food & Beverage $62,832
- Consulting $1.0M
- Travel & Lodging $411,897
- Research $11.7M
About Ipsen Innovation
Ipsen Innovation has made $13.6M in payments to 188 healthcare providers, recorded across 6,490 transactions in the CMS Open Payments database. In 2024, the company paid $5.8M. The top product by payment volume is Dysport ($6.4M).
Payments were distributed across 51 medical specialties. The top specialty by payment amount is Neurology ($523,380 to 42 doctors).
Payment categories include: Food & Beverage ($62,832), Consulting ($1.0M), Research ($11.7M), Travel & Lodging ($411,897).
Ipsen Innovation is associated with 4 products in the CMS Open Payments database, including Dysport, DYSPORT, and Dysport 300 U-1.